EANM’06 – CME Session III
October 1, 2006, 14:30 – 16:00
Molecular Imaging for Drug Development
Moderator: K. Halldin (Stockholm)
Co-Moderator: P. Salvadori (Pisa)
Upon completion of this course the attendee will be able to:
- Understand the quality requirements needed of PET or SPECT tracers used for drug development.
- Describe ways to use imaging in development of drugs within the CNS.
- Describe ways to use imaging in development of drugs for targets outside the brain.
A basic problem in the discovery and development of novel drugs to be used in the therapy of neurological and psychiatric disorders is to find relevant in vitro or in vivo animal models and to be able to extrapolate the results to man. Drug research now benefits from the fast development of functional imaging techniques that trace radiolabeled molecules directly in the human brain. Positron Emission Tomography (PET) and allied techniques use molecules which are labeled with short-lived radionuclides and injected intravenously in experimental animals or human volunteers.
The most straightforward approach is to radiolabel a new potential drug and to trace its uptake, anatomical distribution and binding in brain. An indirect approach is to study how the unlabeled drug inhibits specific radioligand binding. Furthermore, the effects of a novel drug on physiological-biochemical parameters, measured by known radiotracers, can also be assessed. The demonstration of quantitative relationships between drug binding in vivo and drug effects in patients is used to validate targets for drug action, to correlate pharmacological and physiological effects, and to optimise clinical treatment.
Drug Development, PET, Functional Imaging, Radiotracers, Carbon-11, Fluorine-18